Cipla partners with Qilu to license and supply Keytruda biosimilar in the US
A new licensing and supply arrangement may expand availability of a Keytruda biosimilar in the US market.
Source →The trace
How it reaches your house.
Starting from Hybio Pharmaceutical Co., Ltd, we walked the supply graph hop by hop to the goods you buy and the companies you own. Each step is the engine’s reasoning, scored for confidence and cited where a source backs it.
First impact
Cipla →supply upQL2107 (Keytruda biosimilar) in the US
The agreement gives Qilu responsibility for the product's development, registration, and supply in the US, which should increase availability once launched/approved.
“for the exclusive licensing and supply of QL2107, a biosimilar to Keytruda® (pembrolizumab), for the United States”
73% confidenceCited →
Where it lands
What you buy, and what you own.
Goods you buy
QL2107 (Keytruda biosimilar) in the US
Companies you may own
No named companies on this path.
Tap a company to see what it told the SEC could break it.
In the MyPRIA app, this is checked against your own holdings.